Company news

Neurocrine Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022

October 23, 2022

Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference

October 18, 2022

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2022 Financial Results

October 10, 2022

Neurocrine Biosciences Appoints Dr. Ingrid Delaet as Chief Regulatory Officer

September 28, 2022

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022

September 18, 2022

Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress

September 14, 2022

Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress

September 14, 2022

Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences Announce New Survey Results Revealing the Significant Impact OFF Time Has on People with Parkinson's Disease and Their Care Partners

September 11, 2022

Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

September 5, 2022

Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance

August 3, 2022

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results

July 13, 2022

Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022

June 12, 2022

Neurocrine Biosciences to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

June 7, 2022

Neurocrine Biosciences Presents Data on Sleep Disturbances and OFF Time in Patients with Parkinson's Disease and Motor Fluctuations at SLEEP 2022

June 5, 2022

Neurocrine Biosciences Honored at CARES Foundation 22nd Anniversary Gala

June 5, 2022

Neurocrine Biosciences Announces Repurchase of Convertible Notes

May 23, 2022

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data on Tardive Dyskinesia Improvement and Stability of Psychiatric Symptoms at American Psychiatric Association Annual Meeting 2022

May 22, 2022

Neurocrine Biosciences Receives Orphan Drug Designation for Valbenazine as a Treatment for Chorea Associated with Huntington Disease

May 11, 2022

Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance

May 3, 2022

Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference

May 2, 2022

Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week

May 1, 2022

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2022 Financial Results

April 12, 2022

Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022

March 31, 2022

Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022

March 27, 2022

Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan

March 27, 2022

Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting

March 23, 2022

Neurocrine Biosciences to Present at Stifel 2022 CNS Days

March 20, 2022

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022

February 10, 2022

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2021 Financial Results

January 24, 2022

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2021 Net Product Sales Results and Future Program Milestones

January 5, 2022

Neurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 2, 2022

Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease

December 6, 2021

Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer

November 29, 2021

Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders

November 21, 2021

Neurocrine Biosciences Reports Third Quarter 2021 Financial Results

October 31, 2021

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021

October 31, 2021

Neurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting

October 15, 2021

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2021 Financial Results

October 10, 2021

Neurocrine Biosciences Expands Monumental Moments™ Program With World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic

October 7, 2021

Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease

August 4, 2021

Neurocrine Biosciences Reports Second Quarter 2021 Financial Results

August 2, 2021

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results

July 18, 2021

Neurocrine Biosciences Reports First Quarter 2021 Financial Results

May 4, 2021

Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors

April 15, 2021

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results

April 13, 2021

Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)

March 1, 2021

Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results

February 3, 2021

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results

January 19, 2021

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

January 7, 2021

Neurocrine Biosciences Reports Third Quarter 2020 Financial Results

November 8, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 40 decks. Every deck is listed under its year.